WP1066 — Full data
H2 2026
A manuscript covering the prior pediatric study for WP1066 treating brain tumors conducted at Emory University has been drafted and was accepted for publication, expected in the second half of 2026.Source filing
MBRX biotech catalysts & pipeline
MOLECULIN BIOTECH INC · Data as of 2026-10-25
Upcoming catalysts
Annamycin (also known as naxtarubicin) — Full data
Q1 2027
In this episode of CEO Corner, Moleculin Biotech Chairman and CEO Walter Klemp discusses the progress of the Company's Phase 2/3 MIRACLE trial evaluating Annamycin in combination with high-dose cytarabine (HiDAC) for patients with second-line relapsed or refractory acute myeloid leukemia (AML).Source filing
Annamycin (also known as naxtarubicin) — Topline data
2028
● 2028: Primary efficacy data for MIRACLE 2nd line subjectsSource filing
Annamycin (also known as naxtarubicin) — Rolling NDA/BLA submission
2028
● 2028: Begin submission of a Rolling New Drug Application (NDA) for the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLESource filing
Annamycin (also known as naxtarubicin) — NDA/BLA submission
2029
● 2029: NDA submission completeSource filing